<DOC>
	<DOCNO>NCT00232583</DOCNO>
	<brief_summary>The study evaluate rate beta-cell function decline newly diagnose type 2 diabetic patient two different treatment regimen : insulin metformin versus glyburide , metformin pioglitazone .</brief_summary>
	<brief_title>Preservation Beta-cell Function Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This 72 month long randomize clinical trial longitudinally evaluate beta-cell function , well glycemic control inflammatory marker newly diagnose type 2 diabetic patient two different treatment regimen : insulin metformin versus glyburide , metformin pioglitazone .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>type 2 diabetes mellitus diagnose within prior 2 month HbA1c &gt; 7 % time inclusion willing perform intensive diabetes management able comply treatment followup regimen HbA1c &gt; 8 % time randomization creatinine &gt; 1.5 mg/dl liver function test &gt; 3 time upper limit normal severe anemia severe proliferative retinopathy NYHA class III IV heart failure active CAD recent ( within 6 month ) MI pregnant , willing get pregnant , willing practice contraceptive method nonenglish speaking active heavy alcohol illicit drug user ( within past 6 month ) history lactic acidosis</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>TYpe 2 diabetes mellitus</keyword>
	<keyword>Newly diagnose</keyword>
	<keyword>Beta-cell function</keyword>
</DOC>